Treatment Response with Ca-125 in Ovarian Cancer Patients: Comparison among RECIST, WHO, Tridimensional and 3D Volumetric Criteria

被引：0
|
作者：
Oliveira, G. [1 ]
Zondervan, R. [2 ]
Harris, G. [2 ]
Hodge, S. [2 ]
Harisinghani, M. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 192卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan
    Gossner, Gabrielle
    Coleman, Robert L.
    Mutch, David G.
    Horowitz, Neil S.
    Rader, Janet S.
    Gibb, Randall K.
    Powell, Matthew A.
    Herzog, Thomas J.
    GYNECOLOGIC ONCOLOGY, 2006, 103 (01) : 212 - 218
  • [22] Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
    Wilbaux, M.
    Henin, E.
    Oza, A.
    Colomban, O.
    Pujade-Lauraine, E.
    Freyer, G.
    Tod, M.
    You, B.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1517 - 1524
  • [23] MONITORING CA-125 SERUM LEVELS (SL) TO PREDICT TREATMENT OUTCOME IN OVARIAN-CANCER PATIENTS (OCP)
    COLOMBO, N
    ROVELLI, F
    VASSENA, L
    PECORELLI, S
    BONAZZI, C
    MANTOVANI, A
    MANGIONI, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 146 - 146
  • [24] PREOPERATIVE ELEVATION OF CA-125, CA-72 AND CA-15-3 IN PATIENTS WITH NONMUCINOUS EPITHELIAL OVARIAN-CANCER
    ZURAWSKI, VR
    KNAPP, RC
    BAST, RC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 357 - 357
  • [25] CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS
    BEREK, JS
    KNAPP, RC
    MALKASIAN, GD
    LAVIN, PT
    WHITNEY, C
    NILOFF, JM
    BAST, RC
    OBSTETRICS AND GYNECOLOGY, 1986, 67 (05): : 685 - 689
  • [26] CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
    Fang Wang
    Yanfen Ye
    Xia Xu
    Xuehui Zhou
    Jinhua Wang
    Xiaoxiang Chen
    Journal of Ovarian Research, 6
  • [27] Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Zivanovic, Oliver
    Sima, Camelia S.
    Iasonos, Alexia
    Bell-McGuinn, Katherine M.
    Sabbatini, Paul J.
    Leitao, Mario M.
    Levine, Douglas A.
    Gardner, Ginger J.
    Barakat, Richard R.
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (02) : 209 - 214
  • [28] RECIST is more sensitive than CA-125 in detecting disease progression in epithelial ovarian cancer patients treated with maintenance bevacizumab: A secondary analysis of the ROSIA trial
    Lavie, O.
    Feferkorn, I.
    Frenkel, O.
    Segev, Y.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 117 - 117
  • [29] COMPARISON OF CARCINOEMBRYONIC ANTIGEN (CEA), CANCER ANTIGEN-125 (CA-125), AND CARBOHYDRATE ANTIGEN (CA-19-9) SERUM LEVELS IN PATIENTS WITH OVARIAN OR PANCREATIC-CANCER
    SCHENKEN, LL
    PUGH, RP
    TIPPETT, BK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 149 - 149
  • [30] The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer
    Piedimonte, Sabrina
    Kim, Soyoun Rachel
    Clark, Mitchell
    Lheureux, Stephanie
    May, Taymaa
    Bernardini, Marcus
    Atenafu, Eshetu
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S109 - S109
12345